4D Molecular Therapeutics
4D Molecular Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on genetic medicines. The company develops targeted adeno-associated virus gene therapy product candidates using its proprietary Therapeutic Vector Evolution platform. Main revenue drivers currently stem from strategic development collaborations, licensing agreements, and capital markets financing as pipeline candidates advance through clinical trials. 4D Molecular Therapeutics targets patients with severe genetic diseases in ophthalmology, pulmonology, and cardiology across North America and international markets. The company holds a pioneer position in directed evolution vector discovery for targeted tissue delivery of genetic medicines. Headquartered in Emeryville, California, 4D Molecular Therapeutics Inc is listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in 4D Molecular Therapeutics.
- Legal name
- 4D Molecular Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding 4D Molecular Therapeutics
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.07 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)